CK Life Sciences (HKG:0775) expects an attributable loss of HK$126.6 million in 2024, compared with a profit of HK$17.3 million a year prior, a Thursday filing with the Hong Kong bourse said.
The biotechnology company attributed the forecast mainly to a rise in R&D investments and a decline in the fair value of its vineyard portfolio.
Shares of the company were up nearly 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.